NCT01349868View on ClinicalTrials.gov

PT005 MDI Dose Ranging Versus Foradil Aerolizer Study

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

PT005 MDI

PT005 MDI taken as two inhalations

DRUG

Formoterol Fumarate 12 μg (Foradil® Aerolizer®)

Taken as 1 capsule. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece

DRUG

Formoterol Fumarate 24 μg (Foradil® Aerolizer®)

Taken as 2 capsules. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece

OTHER

Placebo MDI

Matching placebo to PT005 MDI taken as two inhalations

Trial Locations (3)

Unknown

Pearl Investigative Site, Clearwater

Pearl Investigative Site, Tampa

Pearl Investigative Site, Spartanburg

Sponsors
All Listed Sponsors
lead

Pearl Therapeutics, Inc.

INDUSTRY